CardioBites: Comprehensive Management of Hypertrophic Cardiomyopathy Beyond Medical TherapySome individuals with hypertrophic cardiomyopathy don’t experience symptoms, while others can present with exertional dyspnea, fatigue, palpitations, lightheadedness, syncope, atypical chest pain, cardiac arrhythmias, or sudden cardiac death (SCD) related to ventricular diastolic dysfunction. This discussion looks at the key aspects of non-pharmacologic management, including red flags for sudden cardiac death, atrial fibrillation, family screening, and exercise. Watch nowCardioBites: Hypertrophic Cardiomyopathy: Disease Mechanisms in Hypertrophic CardiomyopathyHypertrophic Cardiomyopathy (HCM) is a genetic disorder that affects approximately 1 in 500 people. Some individuals with HCM don’t experience symptoms, while others can present with exertional dyspnea, fatigue, palpitations, lightheadedness, syncope, atypical chest pain, cardiac arrhythmias, or sudden cardiac death (SCD) related to ventricular diastolic dysfunction. In this CardioBites video, we explore how the pathogenesis and mechanisms of disease can facilitate effective, timely treatment for patients with HCM. We take a closer look at how both Familial and Non-Familial HCM can be classified as either obstructive or non-obstructive based on their presentation. Obstructive HCM (o-HCM) subtype of HCM has prevalence of 70% and non-obstructive HCM (n-HCM) is 30%. Familial HCM is present in 60% of the patient population with HCM by family history or genetic testing, and non-familial is 40%. Both familial and non-familial can present as O-HCM or n-HCM. Watch nowFuture CardioBites:CardioBites: Hypertrophic Cardiomyopathy: Pharmacologic Therapies for Hypertrophic Cardiomyopathy